Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma
- 31 August 2006
- journal article
- review article
- Published by Elsevier BV in Mayo Clinic Proceedings
- Vol. 81 (8), 1047-1053
- https://doi.org/10.4065/81.8.1047
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2006
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaBlood, 2005
- Osteonecrosis of the Jaw and BisphosphonatesNew England Journal of Medicine, 2005
- Bisphosphonates: Clinical ExperienceThe Oncologist, 2004
- Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing RegimensThe Oncologist, 2004
- Use of Bisphosphonates in Patients With Myeloma and Renal FailureMayo Clinic Proceedings, 2003
- Zoledronic acid in cancer patients with bone metastases: Results of Phase I and II trialsSeminars in Oncology, 2001
- A randomized trial of the effect of clodronate on skeletal morbidity in multiple myelomaBritish Journal of Haematology, 1998
- BisphosphonatesDrugs, 1991
- Phosphorus necrosis of the jaw: 'phossy jaw'British Dental Journal, 1972